{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:50:12Z","timestamp":1792759812446,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40744-024-00685-y","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T17:01:36Z","timestamp":1718038896000},"page":"989-999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria"],"prefix":"10.1007","volume":"11","author":[{"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9329-847X","authenticated-orcid":false,"given":"Eric B.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumik","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"2","key":"685_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/rheumatology\/kew223","volume":"56","author":"L Hamilton","year":"2017","unstructured":"Hamilton L, Barkham N, Bhalla A, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology (Oxford). 2017;56(2):313\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"685_CR2","doi-asserted-by":"publisher","first-page":"rkad039","DOI":"10.1093\/rap\/rkad039","volume":"7","author":"SS Zhao","year":"2023","unstructured":"Zhao SS, Harrison SR, Chan A, et al. Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatol Adv Pract. 2023;7(2):rkad039.","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"685_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"685_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"685_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47(3):343\u201350.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"685_CR6","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","volume":"59","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane GJ, Pathan E, Jones GT, Dean LE. Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford). 2020;59(9):2481\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"685_CR7","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1093\/rheumatology\/keaa900","volume":"60","author":"SS Zhao","year":"2021","unstructured":"Zhao SS, Jones GT, Macfarlane GJ, Hughes DM, Moots RJ, Goodson NJ. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology (Oxford). 2021;60(9):4158\u201365.","journal-title":"Rheumatology (Oxford)"},{"key":"685_CR8","unstructured":"Mease P, McLean R, Blachley T, et al. Impact of achieving ASDAS LDA on disease activity and patient-reported outcome measures among patients with ankylosing spondylitis treated with biologic DMARDs [abstract]. Arthritis Rheumatol. 2021;73(suppl 9)."},{"issue":"5","key":"685_CR9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s40744-023-00586-6","volume":"10","author":"JA Walsh","year":"2023","unstructured":"Walsh JA, Saffore CD, Collins EB, Ostor A. Clinical and economic benefit of advanced therapies for the treatment of active ankylosing spondylitis. Rheumatol Ther. 2023;10(5):1385\u201398.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"685_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/rheumatology\/24.3.242","volume":"24","author":"HS Goie The","year":"1985","unstructured":"Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol. 1985;24(3):242\u20139.","journal-title":"Br J Rheumatol"},{"key":"685_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651","volume-title":"Network meta-analysis for decision making","author":"S Dias","year":"2018","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Network meta-analysis for decision making. New York: Wiley; 2018."},{"issue":"4","key":"685_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5152\/eurjrheum.2018.18162","volume":"5","author":"WP Maksymowych","year":"2018","unstructured":"Maksymowych WP, Strand V, Nash P, et al. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol. 2018;5(4):216\u201323.","journal-title":"Eur J Rheumatol"},{"key":"685_CR13","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016. Available from http:\/\/www.nicedsu.org.uk."},{"key":"685_CR14","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2023","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2023."},{"key":"685_CR15","unstructured":"Seo M, Schmid C. bnma: Bayesian Network Meta-Analysis using \u2018JAGS\u2019. R package version 1.4.0. 2022. Available from https:\/\/CRAN.R-project.org\/package=bnma."},{"key":"685_CR16","unstructured":"Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. In: Proceedings of the 3rd international workshop on distributed statistical computing (DSC 2003); 20\u201322 March 2023; Vienna, Austria."},{"key":"685_CR17","unstructured":"AbbVie Inc. Rinvoq\u00ae\u00a0prescribing information. Updated May\u00a02023."},{"key":"685_CR18","unstructured":"Eli Lily and Company. TALTZ\u00ae prescribing information. Updated February 2024."},{"key":"685_CR19","unstructured":"AbbVie Inc. HUMIRA\u00ae prescribing information. Updated December 2021."},{"key":"685_CR20","unstructured":"Amgen Inc. ENBREL\u00ae prescribing information. Updated October 2023."},{"key":"685_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/rheumatology\/kead598","volume":"63","author":"A Deodhar","year":"2023","unstructured":"Deodhar A, Machado PM, M\u00f8rup M, et al. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2023;63:1195\u20131205.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"685_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s12325-023-02732-6","volume":"41","author":"E Mysler","year":"2024","unstructured":"Mysler E, Burmester GR, Saffore CD, et al. Safety of upadacitinib in immune-mediated inflammatory diseases: systematic literature review of indirect and direct treatment comparisons of randomized controlled trials. Adv Ther. 2024;41(2):567\u201397.","journal-title":"Adv Ther"},{"key":"685_CR23","doi-asserted-by":"publisher","unstructured":"Baraliakos X, \u00d8stergaard M, Poddubnyy D, et al. Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: results from a head-to-head randomized phase\u00a0IIIb study. Arthritis Rheumatol. 2024. https:\/\/doi.org\/10.1002\/art.42852.","DOI":"10.1002\/art.42852"},{"key":"685_CR24","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: Inconsistency in networks of evidence based on randomised controlled trials. 2011. Available from http:\/\/www.nicedsu.org.uk."},{"issue":"5","key":"685_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","volume":"22","author":"SS Mattay","year":"2024","unstructured":"Mattay SS, Zamani M, Saturno D, et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis. Clin Gastroenterol Hepatol. 2024;22(5):961\u201370.e12.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00685-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T07:27:09Z","timestamp":1721460429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00685-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00685-y","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xenofon Baraliakos has received grant\/research support from AbbVie and Novartis; consulting fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB Pharma; speakers\u2019 bureau fees from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, and UCB Pharma; is an editorial board member of the <i>Annals of Rheumatic Diseases<\/i>; is the ASAS President; and is the EULAR President-elect. Christopher D. Saffore is an employee of AbbVie Inc. and may hold stock. Eric B. Collins is an employee of Medicus Economics LLC, which received consulting fees and research support from AbbVie. Bhumik Parikh is an employee of AbbVie Inc. and may hold stock. Xiaolan Ye is an employee of AbbVie Inc. and may hold stock. Jessica A. Walsh has received consulting fees or research grants from AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This publication is based on previously conducted clinical trials and no new clinical trials with human participants or animals were performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}